Orthocell Limited

OCC

AU000000OCC6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:53 31/05/2024 BST			5-day change	1st Jan Change
0.365 ^AUD	-2.67%		-3.95%	-10.98%

05-14	Orthocell's Striate+ Dental Membrane Product Achieves 98.6% Success Rate in Post-Market Clinical Study; Shares Up 3%	MT
04-15	Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%	MT

Orthocell Limited Appoints Matthew Callahan as Director

February 11, 2020 at 08:41 am

Orthocell Limited announced the appointment of Matthew Callahan as director, effective Feb. 10, 2020.

Latest news about Orthocell Limited

Orthocell's Striate+ Dental Membrane Product Achieves 98.6% Success Rate in Post-Market Clinical Study; Shares Up 3%	05-14	MT
Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%	04-15	MT
Orthocell Revenue Soars 19% to AU$1.61 Million in Q1	04-09	MT
Orthocell Completes First Stage of Remplir US Market Authorization Study	03-24	MT
Orthocell Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-23	CI
Orthocell Completes AU$3.5 Million Share Placement	02-22	MT
Orthocell Submits Regulatory Application for Remplir in Singapore	02-13	MT
Orthocell Limited Announces Resignation of Matthew Callahan from the Board	01-15	CI
Orthocell Limited Appoints Kim Beazley AC as an Independent Non-Executive Director	01-14	CI
Orthocell Completes Chair Transition Process	12-22	MT
Orthocell Limited Announces Changes to its Board	12-21	CI
Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023	24/10/23	CI
Orthocell Limited Announces Board Changes	24/10/23	CI
Orthocell Limited Announces Board Changes	22/09/23	CI
Orthocell Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI
Orthocell Secures Over AU$3 Million R&D Tax Rebate	21/06/23	MT
Orthocell Appoints Nonexecutive Chair	29/05/23	MT
Orthocell Limited Announces Board Changes	29/05/23	CI
Orthocell Begins Comparator Study for Product Marketing Initiatives	18/04/23	MT
Orthocell Limited Announces Appointments to its Medical and Scientific Advisory Board	28/03/23	CI
Orthocell Limited Appoints Ravi I. Thadhani as Independent Non-Executive Director	07/03/23	CI
Orthocell Announces Company Secretary Changes	28/02/23	CI
Orthocell Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/02/23	CI
Orthocell's Nerve Repair Product Joins Australian Prosthesis Reimbursement List	01/11/22	MT
Orthocell Says Cell Therapy Effective in Rotator Cuff Injuries	29/09/22	MT

Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. It is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

Sector

Biotechnology & Medical Research

Calendar

04/08/2024 - March 2024 Sales and Revenue Release - Activities Report

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ORTHOCELL LIMITED	-10.98%	50.73M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs